Loading
CI
ChemoCentryx, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 May 2021.
ChemoCentryx, Inc.: what insiders have been doing
ChemoCentryx, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). No insider at ChemoCentryx, Inc. has published a filing in the past twelve months. The most recent one dates from 24 October 2022.
Looking back to 2016, when coverage begins, insiders filed 2 purchases and 13 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
56
Thresholds
n/a
Buy Volume
€99,631
2 ops. · all time
Sell Volume
€138M
13 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$10.83
Analyst consensus
Profitability & ownership
% insiders6.3%
% institutions68.8%
Last declaration on 24 October 2022
Declarations56 total
148,127 sharesCommon StockSEC:0000899243-22-034076:0
91,317 sharesCommon StockSEC:0000899243-22-034081:0
143,306 sharesCommon StockSEC:0000899243-22-034086:0
107,997 sharesCommon StockSEC:0000899243-22-034084:0
10,870 sharesCommon StockSEC:0000899243-22-034068:0
2,393,352 sharesCommon StockSEC:0000899243-22-034075:0
87,658 sharesCommon StockSEC:0000899243-22-034071:0
17,237 sharesCommon StockSEC:0000899243-22-034087:0
9,138 sharesCommon StockSEC:0000899243-22-034077:0
19,898 shares@ US$10.8670.6% of flowCommon StockSEC:0001209191-22-046662:0
14,583 shares@ US$6.2329.4% of flowCommon StockSEC:0001209191-22-044894:0
10,000 shares@ US$50.2257.0% of flowCommon StockSEC:0001209191-22-044891:0
130,000 shares@ US$14.2883.7% of flowCommon StockSEC:0001209191-22-044896:0
7,564 shares@ US$50.22100.0% of flowCommon StockSEC:0001209191-22-044889:0
17,237 shares0Common StockSEC:0001209191-22-039982:0
3,804 shares@ US$25.652610.7% of flowCommon StockSEC:0001209191-22-036438:0
15,723 shares0Common StockSEC:0001209191-22-033031:0
7,726 shares0Common StockSEC:0001209191-22-031763:0
7,726 shares0Common StockSEC:0001209191-22-031750:0
7,726 shares0Common StockSEC:0001209191-22-031761:0
12,500 shares@ US$14.42100.0% of flowCommon StockSEC:0001209191-22-026584:0
25,000 shares@ US$15.90100.0% of flowCommon StockSEC:0001209191-22-004865:0
25 of 56 declarations
About ChemoCentryx, Inc.
ChemoCentryx, Inc. was a U.S.-based biopharmaceutical company historically listed on the NASDAQ under the ticker CCXI and headquartered in Mountain View, California, United States. From an equity-research perspective, it fit the profile of a clinical-stage biotech company with a focus on orally administered therapies for autoimmune diseases, inflammatory disorders, and selected cancers. The company was founded in the 1990s and built its strategy around the discovery and development of small-molecule drugs that target specific immune pathways, especially complement biology and leukocyte trafficking.
Its lead asset was avacopan, marketed as TAVNEOS, an oral therapy used in anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis). This product became the key value driver for the business and the main reason ChemoCentryx attracted attention from specialist biotech investors. Moving from late-stage clinical development into commercialization, TAVNEOS gave the company a clearer pathway to revenue, while also highlighting the attractiveness of differentiated oral medicines in severe immune-mediated diseases. In addition to avacopan, ChemoCentryx had broader research programs in immunology, inflammation, and oncology, but its competitive identity was primarily built around targeted mechanism-of-action innovation rather than a broad commercial portfolio.
Read moreShow less
Competitively, ChemoCentryx operated in a niche biotech segment where value creation depends heavily on clinical data, regulatory milestones, reimbursement dynamics, and launch execution. Its strategic appeal came from addressing serious and relatively rare conditions where an effective oral treatment can potentially command premium pricing and offer a meaningful convenience advantage versus infused or hospital-based alternatives. For investors, the company represented the classic high-risk/high-reward biotechnology model: a concentrated pipeline, high sensitivity to trial outcomes, and meaningful upside if a lead asset gains adoption.
A critical recent development is that ChemoCentryx is no longer an independent publicly traded company. Amgen announced and then completed the acquisition of ChemoCentryx in 2022, meaning CCXI ceased to function as a standalone listed equity after that transaction. As a result, any historical analysis of ChemoCentryx should be viewed through the lens of an acquired asset rather than an ongoing public company. The company’s operating footprint was primarily California-based, with commercial relevance centered on the United States and other highly regulated pharmaceutical markets.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
